Cargando…
Radionuclides in the management of thyroid cancer
Nuclear medicine imaging was born over 60 years ago with imaging of thyroid conditions. Most of our present imaging devices were developed for imaging of the thyroid and thyroid cancer. Millions of patients in over 100 countries have been diagnosed and treated for thyroid cancer using nuclear medici...
Autor principal: | |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
e-Med
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2151327/ https://www.ncbi.nlm.nih.gov/pubmed/18083649 http://dx.doi.org/10.1102/1470-7330.2007.0029 |
_version_ | 1782144722587877376 |
---|---|
author | Buscombe, J.R. |
author_facet | Buscombe, J.R. |
author_sort | Buscombe, J.R. |
collection | PubMed |
description | Nuclear medicine imaging was born over 60 years ago with imaging of thyroid conditions. Most of our present imaging devices were developed for imaging of the thyroid and thyroid cancer. Millions of patients in over 100 countries have been diagnosed and treated for thyroid cancer using nuclear medicine techniques. It remains, however, one of the most dynamic areas of development in nuclear medicine with new roles for positron emission tomography and receptor based imaging. In addition to this is research into combinations of genetic therapy and radioisotopes and receptor based therapy using beta emitting analogues of somatostatin. Despite the use of ultrasound computed tomography and magnetic resonance, nuclear medicine techniques remain central to both imaging and therapy in thyroid disease and the field has recently become one of the most dynamic within the specialty. |
format | Text |
id | pubmed-2151327 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | e-Med |
record_format | MEDLINE/PubMed |
spelling | pubmed-21513272009-12-17 Radionuclides in the management of thyroid cancer Buscombe, J.R. Cancer Imaging Article Nuclear medicine imaging was born over 60 years ago with imaging of thyroid conditions. Most of our present imaging devices were developed for imaging of the thyroid and thyroid cancer. Millions of patients in over 100 countries have been diagnosed and treated for thyroid cancer using nuclear medicine techniques. It remains, however, one of the most dynamic areas of development in nuclear medicine with new roles for positron emission tomography and receptor based imaging. In addition to this is research into combinations of genetic therapy and radioisotopes and receptor based therapy using beta emitting analogues of somatostatin. Despite the use of ultrasound computed tomography and magnetic resonance, nuclear medicine techniques remain central to both imaging and therapy in thyroid disease and the field has recently become one of the most dynamic within the specialty. e-Med 2007-12-17 /pmc/articles/PMC2151327/ /pubmed/18083649 http://dx.doi.org/10.1102/1470-7330.2007.0029 Text en © 2007 International Cancer Imaging Society |
spellingShingle | Article Buscombe, J.R. Radionuclides in the management of thyroid cancer |
title | Radionuclides in the management of thyroid cancer |
title_full | Radionuclides in the management of thyroid cancer |
title_fullStr | Radionuclides in the management of thyroid cancer |
title_full_unstemmed | Radionuclides in the management of thyroid cancer |
title_short | Radionuclides in the management of thyroid cancer |
title_sort | radionuclides in the management of thyroid cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2151327/ https://www.ncbi.nlm.nih.gov/pubmed/18083649 http://dx.doi.org/10.1102/1470-7330.2007.0029 |
work_keys_str_mv | AT buscombejr radionuclidesinthemanagementofthyroidcancer |